Northumbria Healthcare NHS Foundation Trust   Report issue

Foundation Phase 1 Phase 3 Phase 4
Founded: United Kingdom

Organization Overview

First Clinical Trial
2010
NCT01067430
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Northumbria Healthcare NHS Foundation Trust | Northumbria Healthcare NHS FT - Head of R&D

Active Ingredients

Drugs in Phase 4 Trials (2)

diclofenac (voltaren) (1 trial)

torcoxia (1 trial)

Drugs in Phase 3 Trials (4)

apixaban (eliquis) (1 trial)

dabigatran (pradaxa) (1 trial)

edoxaban (savaysa) (1 trial)

rivaroxaban (xarelto) (1 trial)

Drugs in Phase 1 Trials (1)

lisinopril (zestril) (1 trial)

Drugs in Other Trials (4)

amioca starch (1 trial)

maltodextrin (1 trial)

polydextrose (1 trial)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Atrial Fibrillation (Phase 3)

Cerebral Hemorrhage (Phase 3)

Hemorrhage (Phase 3)

Stroke (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 11